Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antimicrobial peptides (AMPs) are short, typically cationic proteins that serve as critical components of the innate immune system and ecological regulators within the gastrointestinal tract. They exert their effects by directly disrupting the cell membranes of pathogens or by modulating the composition of the gut microbiota, thereby influencing host health and disease states. While many AMPs have well-characterized structures, such as defensins and cathelicidins, the specific molecular targets for many secreted peptides in the gut remain 'unknown' or involve complex multi-target interactions with bacterial lipids and host receptors. These molecules are increasingly being investigated as therapeutic agents to treat dysbiosis and enteric infections by selectively pruning the microbiome. Their role extends beyond simple killing, as they also act as signaling molecules that bridge the gap between the microbiome and host epithelial or immune cells.
Direct lysis of microbial membranes, modulation of host immune signaling pathways, and competitive exclusion within the gut ecological niche.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antimicrobial peptide (unspecified) (AMP).